Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 533-546

  Skarlos, P ^a   Christodoulou, C ^b   Kalogeras, K T ^c,d   Eleftheraki, A G ^c   Bobos, M ^d   Batistatou, A ^e   Valavanis, C ^f   Tzaida, O ^f   Timotheadou, E ^d   Kronenwett, R ^g,l   Wirtz, R M ^g,m   Kostopoulos, I ^d   Televantou, D ^d   Koutselini, E ^b   Papaspirou, I ^h   Papadimitriou, C A ⁱ   Pectasides, D ^j   Gogas, H ⁱ   Aravantinos, G ^k   Pavlidis, N ^e   Arapantoni, P ^f   Skarlos, D V ^b   Fountzilas, G ^d   more..

^a Agios Savvas Cancer Hospital   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

^g SIEMENS AG   (Germany)

^h ALEXANDRA HOSPITAL   (Greece)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j HIPPOKRATION HOSPITAL   (Greece)

^k AGII ANARGIRI CANCER HOSPITAL   (Greece)

^l Sividon Diagnostics GmbH   (Germany)

^m STRATIFYER Molecular Pathology GmbH   (Germany)

more..

Author keywords

HER2 enriched subtype; Immunophenotypic subtypes; mRNA expression; mRNA subtypes; Prognostic value; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FORMALDEHYDE; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN; VIMENTIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EMBEDDING; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENOTYPE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84856734732     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1730-9     Document Type: Article

References (35)

1. K Bohmann G Hennig U Rogel C Poremba BM Mueller P Fritz S Stoerkel KL Schaefer 2009 RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods Clin Chem 55 1719 1727 19617290 10.1373/clinchem.2008.122572 1:CAS:528:DC%2BD1MXhtVynt77E
2. G Bonadonna E Brusamolino P Valagussa A Rossi L Brugnatelli C Brambilla M De Lena G Tancini E Bajetta R Musumeci U Veronesi 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410 1246307 10.1056/NEJM197602192940801 1:STN:280:DyaE287gtVKrtA%3D%3D
3. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D (Pubitemid 46698581)
4. MC Cheang SK Chia D Voduc D Gao S Leung J Snider M Watson S Davies PS Bernard JS Parker CM Perou MJ Ellis TO Nielsen 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 19436038 10.1093/jnci/djp082 1:CAS:528:DC%2BD1MXmtlyit74%3D
5. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D (Pubitemid 351413917)
6. C Christodoulou I Kostopoulos HP Kalofonos E Lianos M Bobos E Briasoulis H Gogas E Razis DV Skarlos G Fountzilas 2009 Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation Oncology 76 275 285 19262067 10.1159/000207504 1:CAS:528:DC%2BD1MXkvVGitrk%3D
7. ML Citron DA Berry C Cirrincione C Hudis EP Winer WJ Gradishar NE Davidson S Martino R Livingston JN Ingle EA Perez J Carpenter D Hurd JF Holland BL Smith CI Sartor EH Leung J Abrams RL Schilsky HB Muss L Norton 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol Official J Am Soc Clin Oncol 21 1431 1439 10.1200/JCO.2003.09.081 1:CAS:528:DC%2BD2cXptlCks7s%3D (Pubitemid 46594092)
8. M Colleoni BF Cole G Viale MM Regan KN Price E Maiorano MG Mastropasqua D Crivellari RD Gelber A Goldhirsch AS Coates BA Gusterson 2010 Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer J Clin Oncol Official J Am Soc Clin Oncol 28 2966 2973 10.1200/JCO.2009.25.9549 1:CAS:528:DC%2BC3cXptlajtbY%3D
9. S Di Cosimo J Baselga 2010 Management of breast cancer with targeted agents: importance of heterogeneity (corrected) Nat Rev Clin Oncol 7 139 147 20125090 10.1038/nrclinonc.2009.234
10. R Diallo-Danebrock E Ting O Gluz A Herr S Mohrmann H Geddert A Rody KL Schaefer SE Baldus A Hartmann PJ Wild M Burson HE Gabbert U Nitz C Poremba 2007 Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy Clin Cancer Res 13 488 497 17255270 10.1158/1078-0432.CCR-06-1842 1:CAS:528:DC%2BD2sXoslSltw%3D%3D (Pubitemid 46225354)
11. M Dowsett J Cuzick C Wale J Forbes EA Mallon J Salter E Quinn A Dunbier M Baum A Buzdar A Howell R Bugarini FL Baehner S Shak 2010 Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol Official J Am Soc Clin Oncol 28 1829 1834 10.1200/JCO.2009.24.4798
12. Early Breast Cancer Trialists' Colaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
13. C Falo A Moreno M Varela B Lloveras A Figueras A Escobedo 2007 HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy J Cancer Res Clin Oncol 133 423 429 17245595 10.1007/s00432-006-0176-7 1:CAS:528:DC%2BD2sXls1Sit70%3D (Pubitemid 46800662)
14. G Fountzilas D Skarlos U Dafni H Gogas E Briasoulis D Pectasides C Papadimitriou C Markopoulos A Polychronis HP Kalofonos V Siafaka P Kosmidis E Timotheadou D Tsavdaridis D Bafaloukos P Papakostas E Razis P Makrantonakis G Aravantinos C Christodoulou AM Dimopoulos 2005 Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol Official J Eur Soc Med Oncol (ESMO) 16 1762 1771 10.1093/annonc/mdi366 1:STN:280:DC%2BD2MrlvFGlsw%3D%3D (Pubitemid 41631238)
15. L Gianni L Norton N Wolmark TM Suter G Bonadonna GN Hortobagyi 2009 Role of anthracyclines in the treatment of early breast cancer J Clin Oncol Official J Am Soc Clin Oncol 27 4798 4808 10.1200/JCO.2008.21.4791
16. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve PL Fitzgibbons G Francis NS Goldstein M Hayes DG Hicks S Lester R Love PB Mangu L McShane K Miller CK Osborne S Paik J Perlmutter A Rhodes H Sasano JN Schwartz FC Sweep S Taube EE Torlakovic P Valenstein G Viale D Visscher T Wheeler RB Williams JL Wittliff AC Wolff 2010 American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol Official J Am Soc Clin Oncol 28 2784 2795 10.1200/JCO.2009.25.6529
17. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino JN Ingle MR Cooper DF Hayes KH Tkaczuk G Fleming JF Holland DB Duggan JT Carpenter E Frei 3rd RL Schilsky WC Wood HB Muss L Norton 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol Official J Am Soc Clin Oncol 21 976 983 10.1200/JCO.2003.02. 063 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
18. CA Hudis WE Barlow JP Costantino RJ Gray KI Pritchard JA Chapman JA Sparano S Hunsberger RA Enos RD Gelber JA Zujewski 2007 Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol Official J Am Soc Clin Oncol 25 2127 2132 10.1200/JCO.2006.10.3523 (Pubitemid 46972801)
19. J Kononen L Bubendorf A Kallioniemi M Barlund P Schraml S Leighton J Torhorst MJ Mihatsch G Sauter OP Kallioniemi 1998 Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 844 847 9662379 10.1038/nm0798-844 1:CAS:528:DyaK1cXktlKntr8%3D (Pubitemid 28331029)
20. Laporte S, Jones S, Chapelle C, Jacquin J, Martín M (2009) Taxanes in adjuvant therapy-adjuvant chemotherapy consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials. In: Thirty-second annual CTRC-AACR San Antonio breast cancer symposium. Cancer Research, San Antonio
21. MN Levine VH Bramwell KI Pritchard BD Norris LE Shepherd H Abu-Zahra B Findlay D Warr D Bowman J Myles A Arnold T Vandenberg R MacKenzie J Robert J Ottaway M Burnell CK Williams D Tu 1998 Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National cancer institute of canada clinical trials group J Clin Oncol Official J Am Soc Clin Oncol 16 2651 2658 1:CAS:528:DyaK1cXlsFCguro%3D (Pubitemid 28363028)
22. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol Official J Am Soc Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147
23. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol Official J Am Soc Clin Oncol 23 9067 9072 10.1200/JCO.2004.01.0454
24. BM Muller R Kronenwett G Hennig H Euting K Weber K Bohmann W Weichert G Altmann C Roth KJ Winzer G Kristiansen C Petry M Dietel C Denkert 2011 Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue-a new option for predictive biomarker assessment in breast cancer Diagn Mol Pathol 20 1 10 21326033 10.1097/PDM.0b013e3181e3630c
25. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
26. JS Parker M Mullins MC Cheang S Leung D Voduc T Vickery S Davies C Fauron X He Z Hu JF Quackenbush IJ Stijleman J Palazzo JS Marron AB Nobel E Mardis TO Nielsen MJ Ellis CM Perou PS Bernard 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol Official J Am Soc Clin Oncol 27 1160 1167 10.1200/JCO.2008.18.1370
27. G Pentheroudakis A Batistatou KT Kalogeras R Kronenwett RM Wirtz E Bournakis AG Eleftheraki D Pectasides M Bobos I Papaspirou S Kamina H Gogas AK Koutras N Pavlidis G Fountzilas 2011 Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study Breast Cancer Res Treat 127 179 193 21390496 10.1007/s10549-011-1427-0 1:CAS:528:DC%2BC3MXksFegt7k%3D
28. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D (Pubitemid 46120191)
29. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
30. W Schippinger N Dandachi P Regitnig G Hofmann M Balic R Neumann H Samonigg T Bauernhofer 2007 The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer Am J Clin Pathol 128 630 637 17875515 10.1309/51KPD70348RP6XTE (Pubitemid 47584442)
31. RM Simon S Paik DF Hayes 2009 Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 1446 1452 19815849 10.1093/jnci/djp335
32. M Skacel B Skilton JD Pettay RR Tubbs 2002 Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data Appl Immunohistochem Mol Morphol 10 1 6 11893029 10.1097/00022744-200203000-00001 1:CAS:528:DC%2BD38Xit1eht70%3D (Pubitemid 34178269)
33. DS Tan C Marchio RL Jones K Savage IE Smith M Dowsett JS Reis-Filho 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 27 44 17922188 10.1007/s10549-007-9756-8 1:CAS:528:DC%2BD1cXos1Wnsbs%3D (Pubitemid 352009225)
34. M Tanner D Gancberg A Di Leo D Larsimont G Rouas MJ Piccart J Isola 2000 Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am J Pathol 157 1467 1472 11073807 10.1016/S0002-9440(10)64785-2 1:CAS:528:DC%2BD3cXosFyiu7c%3D
35. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43 19548375 1:CAS:528: DC%2BD2sXhsVOmu74%3D (Pubitemid 46174133)